Japon ilaç üreticisi Astellas Pharma Inc., yaşa bağlı körlüğü tedavi etmek için ilaç geliştiren ve NASDAQ’ta süreç gören Iveric Bio Inc.’i yaklaşık 5,9 milyar dolar karşılığında satın alacağını duyurdu. Astellas Pharma ve Iveric Bio tarafından yapılan açıklamada, muahedenin nakit ve borçla finanse edileceği ve Astellas Pharma’nın pay başına 40 dolar teklif ettiği belirtildi.
patronlardunyasi.com
| Çerez | Süre | Açıklama |
|---|---|---|
| cookielawinfo-checkbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
| cookielawinfo-checkbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
| cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
| cookielawinfo-checkbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
| cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
| viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |
